MNKD MannKind Corporation

1.79
+0.1  (+6%)
Previous Close 1.69
Open 1.73
52 Week Low 0.8
52 Week High 2.48
Market Cap $381,516,537
Shares 213,137,730
Float 210,988,251
Enterprise Value $442,505,763
Volume 3,957,627
Av. Daily Volume 3,724,906
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
AFREZZA
Type 1/2 diabetes
Approved
Approved
Approved June 27, 2014.

Latest News

  1. WESTLAKE VILLAGE, Calif., June 15, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced that new data from clinical studies of Afrezza® (insulin human) Inhalation Powder was presented at the American Diabetes Association's 80th Scientific Sessions, June 12-16, 2020.

    The data presented includes:

    • A comprehensive post hoc analysis of four unique studies assessing the safe and effective dosing of Afrezza in patients with type 1 diabetes1 (Poster 1023)
    • An analysis demonstrating treatment with Afrezza is associated with weight loss in patients with type 2 diabetes, compared to weight gain with injected mealtime insulin2 (Poster 1024)
    • An evaluation of a comprehensive two year safety study showing that significant changes in FEV1

    WESTLAKE VILLAGE, Calif., June 15, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced that new data from clinical studies of Afrezza® (insulin human) Inhalation Powder was presented at the American Diabetes Association's 80th Scientific Sessions, June 12-16, 2020.

    The data presented includes:

    • A comprehensive post hoc analysis of four unique studies assessing the safe and effective dosing of Afrezza in patients with type 1 diabetes1 (Poster 1023)
    • An analysis demonstrating treatment with Afrezza is associated with weight loss in patients with type 2 diabetes, compared to weight gain with injected mealtime insulin2 (Poster 1024)
    • An evaluation of a comprehensive two year safety study showing that significant changes in FEV1 (as a measure of pulmonary function) during treatment with Afrezza are both uncommon and generally transient in nature3 (Oral Abstract 235)

    "We are pleased to present these clinical studies detailing the safe and effective use of Afrezza at this year's virtual ADA Scientific Sessions," stated David Kendall, MD, Chief Medical Officer MannKind. "These studies provide further support of the effectiveness and clinical safety of Afrezza therapy and offer important insights on effective dosing of Afrezza, the favorable effect of Afrezza on body weight, and the improvement in clinical outcomes possible when converting patients to Afrezza therapy." 

    Highlights of the presentations are described below. See the appendix for presentation details.

    Poster 1023: Dose Titration and Clinical Effects of Inhaled Technosphere® Insulin Compared with Mealtime Subcutaneous (SC) Analog Insulin Therapy in Type 1 Diabetes (T1D)

    • Ultra rapid-acting Afrezza can be safely and effectively dosed at 1.5 to 2.0 times that of injected mealtime insulin
    • This dosing ratio appears to be consistent across a range of A1C responses
    • Afrezza's ultra rapid-acting profile may supersede the perceived precision of injected mealtime insulin dosing and provides patients the ability to flexibly dose based on glycemic response

    Poster 1024: Technosphere® Insulin Added to Basal Insulin Is Associated with Less Weight Gain than Basal Insulin plus Insulin Aspart or Insulin Analog (aspart) 70/30 Mixture in Type 2 DM

    • Patients with type 2 diabetes treated with Afrezza showed modest weight loss while those treated with insulin aspart or insulin aspart mix resulted in weight gain 
    • The weight difference estimate between Afrezza and insulin aspart was 1.83 pounds
    • The weight difference estimate between Afrezza and biaspart insulin was 3.17 pounds
    • The effect on body weight was independent of the magnitude of improvement in glucose control

    Oral Abstract 235: Incidence of Significant Changes in Pulmonary Function during A 2-year Study with Inhaled Technosphere® Insulin

    • Prior clinical studies have shown a modest (~40 ml) difference in mean change in FEV1 over two years when comparing treatment with Afrezza to other diabetes therapies
    • The majority (88%) of individuals treated with Afrezza had no significant change in FEV1 measured at any time
    • Overall, 98% of patients on Afrezza (vs. 99% of usual care) had either no significant change (≥15%) or were observed to have only a transient change in FEV1 over the two years of study

    About Afrezza®

    Available by prescription, Afrezza® (insulin human) Inhalation Powder is an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus. Afrezza consists of a dry powder formulation of human insulin delivered from a small and portable inhaler. Administered at the beginning of a meal, Afrezza dissolves rapidly upon inhalation to the lung and passes quickly into the bloodstream (in less than one minute). This rapid absorption allows Afrezza to begin reducing blood sugar levels within minutes of administration. Afrezza is available in 4-unit, 8-unit and 12-unit single-dose cartridges of insulin powder that can be used, as prescribed by a health care professional, in combination with other diabetes medications to achieve target blood sugar levels. For Afrezza doses exceeding 12 units, patients may use a combination of existing cartridge strengths. For more information about Afrezza, please visit www.afrezza.com.

    About MannKind Corporation

    MannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide.  MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.

    Forward-Looking Statements

    This press release contains forward-looking statements that involve risks and uncertainties. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties detailed in MannKind's filings with the SEC. For a discussion of these and other factors, please refer to MannKind's annual report on Form 10-K for the year ended December 31, 2019 as well as MannKind's other filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

    MannKind Contact:

    Investor Relations

    818-661-5000

    kindcorp.com

    Appendix – Presentation Details

    (1) Poster Presentation: Dose Titration and Clinical Effects of Inhaled Technosphere® Insulin Compared with Mealtime Subcutaneous (SC) Analog Insulin Therapy in Type 1 Diabetes (T1D)

    Presenter: David M. Kendall, M.D.

    Poster No. 1023-P

    Date/Time: Saturday, June 13; 10 AM CT

    (2) Poster Presentation: Technosphere® Insulin Added to Basal Insulin Is Associated with Less Weight Gain than Basal Insulin plus Insulin Aspart or Insulin Analog (aspart) 70/30 Mixture in Type 2 DM

    Presenter: David M. Kendall, M.D.

    Poster No: 1024-P

    Date/Time: Saturday, June 13; 10 AM CT

    (3) Oral Presentation: Incidence of Significant Changes in Pulmonary Function during A 2-year Study with Inhaled Technosphere® Insulin

    Presenter: David M. Kendall, M.D.

    Poster No: 235-OR

    Date/Time: Sunday, June 14; 5:30 PM CT

    Primary Logo

    View Full Article Hide Full Article
  2. WESTLAKE VILLAGE, Calif., June 13, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced that data from a new clinical study of Afrezza® (insulin human) Inhalation Powder will be presented at the American Diabetes Association's 80th Scientific Sessions during the ePoster session (Poster 990) on Saturday, June 13, 2020.

    The lead author, Mark Kipnes, MD (Diabetes and Glandular Disease Clinic, San Antonio, Texas) presented clinical data from an investigator-initiated observational "switch" study that evaluated quality of life and glucose control in patients with type 2 diabetes previously treated with injected mealtime insulin. Following conversion to Afrezza, patients were followed for 14 weeks, and glucose control (measured…

    WESTLAKE VILLAGE, Calif., June 13, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced that data from a new clinical study of Afrezza® (insulin human) Inhalation Powder will be presented at the American Diabetes Association's 80th Scientific Sessions during the ePoster session (Poster 990) on Saturday, June 13, 2020.

    The lead author, Mark Kipnes, MD (Diabetes and Glandular Disease Clinic, San Antonio, Texas) presented clinical data from an investigator-initiated observational "switch" study that evaluated quality of life and glucose control in patients with type 2 diabetes previously treated with injected mealtime insulin. Following conversion to Afrezza, patients were followed for 14 weeks, and glucose control (measured by both A1C and glucose time in range), rates of hypoglycemia and quality of life were assessed.

    Study subjects experienced a significant (0.8%) reduction in A1C levels at the end of the 14-week treatment period after switching from their injected mealtime insulin to Afrezza. Subjects maintained 66-69% "time in range" (time with glucose values in the range of 70-180 mg/dL) and reduced the time spent with glucose <90 mg/dL. Afrezza therapy resulted in a significant improvement in diabetes quality of life scores. 

    "This study shows that Afrezza treatment—combined with the use of continuous glucose monitoring—can improve overall glucose control while maintaining time in range. Importantly, the study also demonstrates a reduction in blood glucose levels without additional hypoglycemia," stated Dr. Kipnes. "In addition, after switching to Afrezza, these individuals reported an improvement in quality of life measures. This study demonstrates that by rapidly adjusting Afrezza doses, improved clinical outcomes were possible, and patients reported less burden from their diabetes treatment."

    MannKind provided financial support and study product for use in this study. 

    About Afrezza®

    Available by prescription, Afrezza® (insulin human) Inhalation Powder is an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus. Afrezza consists of a dry powder formulation of human insulin delivered from a small and portable inhaler. Administered at the beginning of a meal, Afrezza dissolves rapidly upon inhalation to the lung and passes quickly into the bloodstream (in less than one minute). This rapid absorption allows Afrezza to begin reducing blood sugar levels within minutes of administration. Afrezza is available in 4-unit, 8-unit and 12-unit single-dose cartridges of insulin powder that can be used, as prescribed by a health care professional, in combination with other diabetes medications to achieve target blood sugar levels. For Afrezza doses exceeding 12 units, patients may use a combination of existing cartridge strengths. For more information about Afrezza, please visit www.afrezza.com.

    About MannKind Corporation

    MannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.

    Forward-Looking Statements

    This press release contains forward-looking statements that involve risks and uncertainties. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties detailed in MannKind's filings with the SEC. For a discussion of these and other factors, please refer to MannKind's annual report on Form 10-K for the year ended December 31, 2019 as well as MannKind's other filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

    MannKind Contact:

    Investor Relations

    818-661-5000

    Primary Logo

    View Full Article Hide Full Article
  3. Conference Call to Begin Today at 5:00 PM ET

    • 1Q 2020 Afrezza Net Revenue of $8.0 million; +58% vs. 1Q 2019
    • 1Q 2020 Afrezza gross profit 48% vs. 21% in 1Q 2019
    • Non-GAAP Net Cash Used in Operating Activities in 1Q 2020 was $11.2 million; a reduction of 53% vs. 1Q 2019

    WESTLAKE VILLAGE, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter ended March 31, 2020.

    "We are pleased to report first quarter Afrezza net revenue of $8.0 million, which is 58% higher than the same quarter in 2019," said Michael Castagna, Chief Executive Officer of MannKind Corporation.  "We believe that some of the increased revenue this quarter reflects the impact of patients stocking up on extra refills…

    Conference Call to Begin Today at 5:00 PM ET

    • 1Q 2020 Afrezza Net Revenue of $8.0 million; +58% vs. 1Q 2019
    • 1Q 2020 Afrezza gross profit 48% vs. 21% in 1Q 2019
    • Non-GAAP Net Cash Used in Operating Activities in 1Q 2020 was $11.2 million; a reduction of 53% vs. 1Q 2019

    WESTLAKE VILLAGE, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter ended March 31, 2020.

    "We are pleased to report first quarter Afrezza net revenue of $8.0 million, which is 58% higher than the same quarter in 2019," said Michael Castagna, Chief Executive Officer of MannKind Corporation.  "We believe that some of the increased revenue this quarter reflects the impact of patients stocking up on extra refills in advance of the stay-at-home orders that have since been implemented across the country.  In response to the COVID-19 pandemic, we have rapidly implemented digital tools and programs to help our sales force and our Afrezza prescribers navigate this challenging time for our healthcare system.  In addition, our manufacturing and development team in Connecticut remain focused on maintaining supply of Afrezza and meeting our obligations under our collaboration with United Therapeutics."

    Total revenues were $16.2 million for the first quarter of 2020, reflecting Afrezza net revenue of $8.0 million and collaboration and services revenue of $8.2 million. Afrezza net revenue increased 58% compared to $5.1 million in the first quarter of 2019, primarily driven by higher product demand as well as a price increase and a more favorable mix of cartridges. Collaboration and services revenue for the first quarter of 2020 decreased $4.2 million compared to the first quarter of 2019, primarily due to the substantial completion of the research agreement with United Therapeutics in the second quarter of 2019. 

    Afrezza gross profit for the first quarter of 2020 was $3.8 million vs. $1.1 million in the same period of 2019, a 263% increase that was driven primarily by higher Afrezza revenue.  Cost of goods sold increased by $0.1 million which included an increase related to Afrezza unit sales growth and an inventory write-off offset by a greater amount of costs capitalized to inventory due to a higher volume of manufacturing activities in the first quarter of 2020. Gross margin in the first quarter of 2020 increased to 48%, our highest gross margin to date, from 21% for the same quarter in 2019, primarily due to higher Afrezza revenue.

    Selling, general and administrative expenses for the first quarter of 2020 were $14.4 million compared to $25.7 million for the first quarter of 2019. This 44% decrease was primarily due to $9.3 million spent on direct-to-consumer television advertising in 2019, which was not repeated in 2020, a $1.1 million decrease in promotional and marketing activities and $0.8 million decrease in personnel and employee related costs.  

    Net interest expense for the first quarter of 2020 was $2.2 million compared to $1.4 million for the first quarter of 2019. This $0.8 million increase was due to a higher balance of outstanding principal and an increase in the interest rate of certain promissory notes. 

    The net loss for the first quarter of 2020 was $9.3 million, or $0.04 per share, compared to a $14.9 million net loss in the first quarter of 2019, or $0.08 per share. The lower net loss is mainly attributable to a decrease in operating expenses of $7.6 million. The reduction in the net loss per share was impacted by the lower operating expenses and a greater number of outstanding shares.

    Cash, cash equivalents and restricted cash at March 31, 2020 was $39.2 million compared to $50.2 million at December 31, 2019, which also included short-term investments of $20.0 million. The decrease was primarily due to net cash used in operating activities of $11.2 million in the first quarter of 2020. 

    Non-GAAP Measures

    Certain financial information contained in this press release is presented on both a reported basis (GAAP) and a non-GAAP basis.  Reported results were prepared in accordance with GAAP whereas non-GAAP measures exclude items described in the reconciliation tables below.  Non-GAAP financial information is intended to portray the results of our baseline performance, supplement or enhance management, analysts and investors overall understanding of our underlying financial performance and facilitate comparisons among current and past periods.  The non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.

        Three Months Ended March 31,  
        2020     2019     $ Change     % Change  
    Net cash used in operating activities   $ (11,219 )   $ (11,597 )   $ (378 )     (3 %)
    Exclude United Therapeutic milestone payment received           (12,500 )     (12,500 )     (100 %)
    Non-GAAP cash used in operating activities   $ (11,219 )   $ (24,097 )   $ (12,878 )     (53 %)

    Conference Call

    MannKind will host a conference call and presentation webcast to discuss these results today at 5:00 p.m. Eastern Time. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at http://www.mannkindcorp.com under News & Events. 

    A telephone replay of the call will be accessible for approximately 14 days following completion of the call by dialing (844) 512-2921 or (412) 317-6671 and use the participant passcode: 7127207#. A replay will also be available on MannKind's website for 14 days.

    About MannKind Corporation

    MannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide.  MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.

    Forward-Looking Statements

    This press release contains forward-looking statements that involve risks and uncertainties. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties detailed in MannKind's filings with the SEC, including risks related to the COVID-19 pandemic. For a discussion of these and other factors, please refer to MannKind's annual report on Form 10-K for the year ended December 31, 2019 as well as MannKind's other filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

    Company Contact:

    818-661-5000

    MANNKIND CORPORATION
    CONDENSED CONSOLIDATED BALANCE SHEETS
    (Unaudited)
    (In thousands except share data)

      March 31, 2020     December 31, 2019  
    ASSETS              
    Current assets:              
    Cash and cash equivalents $ 38,868     $ 29,906  
    Restricted cash   316       316  
    Short-term investments         19,978  
    Accounts receivable, net   5,032       3,513  
    Inventory   3,231       4,155  
    Prepaid expenses and other current assets   1,901       2,889  
    Total current assets   49,348       60,757  
    Property and equipment, net   26,517       26,778  
    Other assets   4,347       6,190  
    Total assets $ 80,212     $ 93,725  
                   
    LIABILITIES AND STOCKHOLDERS' DEFICIT              
    Current liabilities:              
    Accounts payable $ 6,731     $ 4,789  
    Accrued expenses and other current liabilities   18,326       15,904  
    Short-term note payable   5,101       5,028  
    Deferred revenue — current   30,840       32,503  
    Recognized loss on purchase commitments — current   7,250       7,394  
    Total current liabilities   68,248       65,618  
    Promissory notes   70,022       70,020  
    Accrued interest — promissory notes   3,259       2,002  
    Long-term Midcap credit facility   38,893       38,851  
    Senior convertible notes   5,000       5,000  
    Recognized loss on purchase commitments — long term   82,987       84,639  
    Operating lease liability   2,155       2,514  
    Deferred revenue  — long term   1,772       8,344  
    Milestone rights liability   5,926       7,263  
    Total liabilities   278,262       284,251  
    Stockholders' deficit:              
    Undesignated preferred stock, $0.01 par value — 10,000,000 shares authorized;
      no shares issued or outstanding as of March 31, 2020 and December 31, 2019
             
    Common stock, $0.01 par value - 280,000,000 shares authorized, 213,137,684 and 211,787,573
      shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively
      2,131       2,118  
    Additional paid-in capital   2,801,044       2,799,278  
    Accumulated other comprehensive loss         (19 )
    Accumulated deficit   (3,001,225 )     (2,991,903 )
    Total stockholders' deficit   (198,050 )     (190,526 )
    Total liabilities and stockholders' deficit $ 80,212     $ 93,725  
                   

    MANNKIND CORPORATION
    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
    (Unaudited)
    (In thousands, except per share amounts)

      Three Months Ended March 31,  
      2020     2019  
    Revenues:              
    Net revenue — commercial product sales $ 8,000     $ 5,076  
    Revenue — collaborations and services   8,235       12,372  
    Total revenues   16,235       17,448  
    Expenses:              
    Cost of goods sold   4,164       4,020  
    Cost of revenue — collaborations and services   3,362       1,537  
    Research and development   1,755       1,667  
    Selling, general and administrative   14,350       25,673  
    Impairment of commitment asset   1,521        
    Gain on foreign currency translation   (1,796 )     (1,935 )
    Total expenses   23,356       30,962  
    Loss from operations   (7,121 )     (13,514 )
    Other (expense) income:              
    Interest income   133       318  
    Interest expense on notes   (1,071 )     (593 )
    Interest expense on promissory notes   (1,259 )     (1,080 )
    Other expense   (4 )     (14 )
    Total other expense   (2,201 )     (1,369 )
    Loss before provision for income taxes   (9,322 )     (14,883 )
    Provision for income taxes          
    Net loss $ (9,322 )   $ (14,883 )
    Net loss per share - basic and diluted $ (0.04 )   $ (0.08 )
    Shares used to compute basic and diluted net loss per share   212,467       187,434  

     

    Primary Logo

    View Full Article Hide Full Article
  4. WESTLAKE VILLAGE, Calif., April 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, May 6, 2020.

    Presenting from the Company will be its Chief Executive Officer, Michael Castagna and Chief Financial Officer, Steven Binder.

    Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at http://www.mannkindcorp.com under News & Events. 

    A telephone replay of the call will be accessible for approximately 14 days following completion of the call by dialing (844) 512-2921 or (412) 317-6671…

    WESTLAKE VILLAGE, Calif., April 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, May 6, 2020.

    Presenting from the Company will be its Chief Executive Officer, Michael Castagna and Chief Financial Officer, Steven Binder.

    Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at http://www.mannkindcorp.com under News & Events. 

    A telephone replay of the call will be accessible for approximately 14 days following completion of the call by dialing (844) 512-2921 or (412) 317-6671 and use the participant passcode: 7127207#. A replay will also be available on MannKind's website for 14 days.

    About MannKind Corporation

    MannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide.  MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.

    Company Contact:
    Phone: (818) 661-5000
    Email:

    Primary Logo

    View Full Article Hide Full Article
  5. WESTLAKE VILLAGE, Calif., March 24, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that Jennifer Grancio has been appointed to its Board of Directors, effective March 23, 2020. Ms. Grancio will also serve as a member of the Audit Committee of the Board. Ms. Grancio brings to MannKind over twenty years of financial services experience and an expertise in creating disruptive business models.

    "We are excited to welcome Ms. Grancio and her years of invaluable leadership to our board of directors," said Kent Kresa, Chairman of the Board. "Her financial services leadership experience will be an essential asset for MannKind as the company continues to grow. We are committed to surrounding ourselves with the best talent…

    WESTLAKE VILLAGE, Calif., March 24, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that Jennifer Grancio has been appointed to its Board of Directors, effective March 23, 2020. Ms. Grancio will also serve as a member of the Audit Committee of the Board. Ms. Grancio brings to MannKind over twenty years of financial services experience and an expertise in creating disruptive business models.

    "We are excited to welcome Ms. Grancio and her years of invaluable leadership to our board of directors," said Kent Kresa, Chairman of the Board. "Her financial services leadership experience will be an essential asset for MannKind as the company continues to grow. We are committed to surrounding ourselves with the best talent available, and the appointment of Ms. Grancio reflects that effort."

    Ms. Grancio served as a founder and executive with BlackRock's iShares business from 1999 to 2018. She spearheaded the distribution of iShares in the United States and Europe and acted as the Global Head of Marketing and Partnerships for BlackRock's indexing service. Through those efforts, Ms. Grancio established herself as a global leader in exchange-traded and mutual funds.

    Since her time at BlackRock, she founded Grancio Capital, where she consults with company leaders on the best ways to expand market reach and how to build effective teams to do so. Previously, she was a senior associate with PricewaterhouseCoopers, a management consulting firm.

    Ms. Grancio has served as a board member for Ethic, a sustainable investing firm, since November 2019. She serves on the board of Harvest Savings & Wealth as of Q1 2020 and is on the advisory boards of Say Technologies and m+ funds. Ms. Grancio is also active as a strategic advisor and speaker to organizations that are committed to developing diverse senior leaders and to developing leadership in young women.

    She earned a bachelor's degree in economics and international relations from Stanford University, and an MBA degree in strategy and finance from Columbia Business School.

    With the addition of Ms. Grancio, there are nine members of the MannKind Board of Directors.

    About MannKind Corporation
    MannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.

    Forward-Looking Statements
    This press release contains forward-looking statements that involve risks and uncertainties. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties detailed in MannKind's filings with the SEC. For a discussion of these and other factors, please refer to MannKind's annual report on Form 10-K for the year ended December 31, 2019 as well as MannKind's other filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

    Company Contact:
    818-661-5000

    Primary Logo

    View Full Article Hide Full Article
View All MannKind Corporation News